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A better understanding of early brain changes that precede loss of independence in diseases like 26 
Alzheimer’s disease (AD) is critical for development of disease-modifying therapies. Quantitative 27 
MRI, such as T2 relaxometry, can identify microstructural changes relevant to early stages of 28 
pathology. Recent evidence suggests heterogeneity of T2 may be a more informative measure of 29 
early pathology than absolute T2.  Here we test whether T2 markers of brain integrity precede the 30 
volume changes we know are present in established AD and whether such changes are most marked 31 
in medial temporal lobe (MTL) subfields known to be most affected early in AD. We show that T2 32 
heterogeneity was greater in people with mild cognitive impairment (MCI; n=49) compared to 33 
healthy older controls (n=99) in all MTL subfields, but this increase was greatest in MTL cortices, 34 
and smallest in dentate gyrus. This reflects the spatio-temporal progression of neurodegeneration in 35 
AD. T2 heterogeneity in the entorhinal cortex also predicted cognitive decline over a year in people 36 
with MCI, where measures of volume or T2 in any other subfield or whole hippocampus could not. 37 
Increases in T2 heterogeneity in MTL cortices may reflect localised pathological change and may 38 
present as one of the earliest detectible brain changes prior to atrophy. Finally, we describe a 39 
mechanism by which memory, as measured by accuracy and reaction time on a paired associate 40 
learning task, deteriorates with age. Age-related memory deficits were explained in part by lower 41 
subfield volumes, which in turn were directly associated with greater T2 heterogeneity. We propose 42 
that tissue with high T2 heterogeneity represents extant tissue at risk of permanent damage but with 43 
the potential for therapeutic rescue. This has implications for early detection of neurodegenerative 44 




Accurate early diagnosis of Alzheimer’s disease (AD) is likely a necessity for development of 47 
disease-modifying therapies (Cummings et al., 2014, Alzheimer's Association, 2015). Manifestation 48 
of cognitive symptoms, although required for clinical diagnosis, is a relatively late stage in the 49 
pathological process (Jack et al., 2010). Thus, clinical interventions after the appearance of cognitive 50 
deficits may be too late to restore brain health. A better understanding of the brain changes that 51 
precede loss of daily independence will help design early markers.  52 
Structural and quantitative MRI show promise in their ability to identify changes in the brain that 53 
indicate early Alzheimer’s pathology. Identifying which people with mild cognitive impairment 54 
(MCI) will progress to AD dementia has been shown to be possible by measuring the volume of 55 
subfields within the medial temporal lobe (MTL) (Chételat et al., 2008, de Flores et al., 2015a, de 56 
Flores et al., 2015b, deToledo-Morrell et al., 2004, Apostolova et al., 2006, Apostolova et al., 2010). 57 
In these groups, large changes in volume tend to indicate significant, and likely irreversible, atrophy. 58 
Smaller scale microstructural changes that occur prior to volume loss could help to identify patients 59 
in which such a treatment is to be optimally effective.  60 
Recently, we demonstrated that the distribution width of T2 relaxation time (T2 heterogeneity) in the 61 
hippocampus predicted cognitive decline over a year in a group of people with MCI (Wearn et al., 62 
2020a). We propose that T2 distribution widens because of different pathological hallmarks having 63 
opposing effects on T2, causing increased apparent heterogeneity without any change in absolute T2 64 
(distribution midpoint). For example, non-haem iron, oligomers and plaques of β-amyloid (Aβ), and 65 
neurofibrillary tangles (NFTs) which build up around the MTL in early Alzheimer's disease (Braak 66 
and Braak, 1991, Braak and Braak, 1995, Selkoe and Hardy, 2016, Smith et al., 2010) all cause T2 to 67 
decrease (Meadowcroft et al., 2015, House et al., 2008). In contrast, tissue alterations preceding 68 
necrosis cause cell membrane breakdown and oedema which increase the motility of water within a 69 
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given region, subsequently causing T2 to increase (Laakso et al., 1996, Symms et al., 2004). Gliosis, 70 
another hallmark of brain injury that commonly follows neurodegeneration is also indicated by 71 
increased T2 relaxation time (Briellmann et al., 2002, Ingelsson et al., 2004, Lee et al., 2013). These 72 
opposing factors necessitate examination of the heterogeneity of T2, rather than midpoint, for more 73 
accurate identification of microstructural impairment. This, we propose, is a reason for the lack of 74 
clear consensus from previous studies of T2 in AD, which exclusively look at absolute T2 (see Tang 75 
et al. (2018) for a review). 76 
Our previous research focused on T2 changes in the hippocampus as a whole (Wearn et al., 2020a). 77 
However, the hippocampus is not a uniform structure, rather, it comprises cytoarchitectonic subfields 78 
with distinct cellular structure, connectivity, functionality, and disease susceptibility (Duvernoy et 79 
al., 2013). NFTs first build up in the transentorhinal region of the MTL (Braak and Braak, 1995), 80 
which roughly corresponds to Brodmann area 35 (BA35), but also includes some of the lateral 81 
portion of entorhinal cortex (EC) (Xie et al., 2018). They then spread through EC, then to CA1, 82 
subiculum, other CA regions and finally dentate gyrus (DG) (Braak and Braak, 1995, Braak and 83 
Braak, 1991, Fukutani et al., 1995, Fukutani et al., 2000). Many of these changes occur even before 84 
symptom onset (Braak and Braak, 1991, Jack et al., 2003, Fukutani et al., 1995), highlighting their 85 
potential as prodromal markers. Reflective of histopathology, hippocampal volume loss due to AD is 86 
widespread across the hippocampus but is generally non-uniform across subfields, with most atrophy 87 
seen in CA1 (Adler et al., 2018, La Joie et al., 2013, Mueller et al., 2010, Wolk et al., 2017, Kerchner 88 
et al., 2012, Sarazin et al., 2010, Frisoni et al., 2008, Frisoni et al., 2006). Volume loss is less severe 89 
in the hippocampus of people with MCI, often restricted to CA1 and, in many cases, the subiculum 90 
(Pluta et al., 2012, Mueller et al., 2010, Tang et al., 2014), with some evidence for a relative sparing 91 
of the stratum radiatum/lacunosum/moleculare (Su et al., 2018). This atrophy pattern has even been 92 
shown in people who subjectively report cognitive decline but who have normal cognition as 93 
measured by standard cognitive tests (Perrotin et al., 2015). For a review see de Flores et al. (2015b). 94 
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Literature on quantitative T2 in MTL subfields in the context of AD is limited to very few ex vivo 95 
studies (Huesgen et al., 1993, Antharam et al., 2012). As with the rest of the literature, these papers 96 
are focused on absolute T2. Antharam et al. (2012) do note that the distribution width of T2 within 97 
the main hippocampal subfields (CA4-DG and CA1-3) is wider in slices from AD patients than age-98 
matched controls. However, they do not perform detailed analyses of the differences of distribution 99 
width between subfields. In a publication of pilot data from our group, Knight et al. (2019) 100 
concluded that T2 heterogeneity in MTL subfields can improve accuracy in distinguishing between 101 
healthy controls, those with MCI and Alzheimer’s disease patients. We know of no other studies that 102 
have explored quantitative T2 in subfields of the MTL in vivo.  103 
The analyses in this paper are presented in two parts. In the first part, we test whether differences in 104 
T2 heterogeneity between subfields could distinguish healthy aging from MCI – important when 105 
considering T2 as a clinic tool to guide prognosis in MCI. We also analyse absolute T2 (distribution 106 
midpoint) to verify that it is heterogeneity and not absolute values that shift. Hypotheses:  107 
1. The effect size of T2 heterogeneity increase in MCI (compared to healthy controls) will differ 108 
by subfield, reflective of the spatio-temporal progression of neurodegeneration in AD. 109 
Accordingly, we expect to see greatest T2 heterogeneity in MTL cortical regions (BA35 and 110 
EC), followed by CA and SUB regions, and the least amount of heterogeneity in DG. 111 
2. T2 heterogeneity in MTL subfields will better predict cognitive decline than in whole 112 
hippocampus in people with mild cognitive impairment. 113 
In the second part, we use path analysis to demonstrate the likely temporal sequence of 114 
neuroanatomical and behavioural changes in ageing. These are important to understand so that we 115 
track the right process at the right disease stage. Hypotheses: 116 
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3. Greater T2 heterogeneity indicates early damage that will lead to macroscopic structural 117 
change, and therefore will statistically mediate the relationship between age and volume of 118 
MTL subfields.  119 
4. Subfield volume is indicative of macroscopic structural change, and therefore will mediate 120 
the relationship between T2 heterogeneity and cognitive performance. 121 
 122 
  123 
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MATERIAL AND METHODS 124 
The following methods are adapted from those presented by Wearn et al. (2020a). 125 
The analyses in this paper combine data from two prospective longitudinal studies similar in cohort 126 
demographics and study design. No participants took part in both studies. Both studies are detailed in 127 
the following section. Where data collected are not identical between cohorts, we have normalised 128 
equivalent metrics within cohort and combined data after normalisation. 129 
Participants  130 
Participants fulfilling the Petersen criteria (Albert et al., 2011) for diagnosis of MCI were recruited to 131 
both studies (Study 1: n=30, Study 2: n=29). Healthy older people (HC), with no history of memory 132 
problems or significant neurological disorders were recruited as controls to each study (Study 1: 133 
n=61; Study 2: n=56). All healthy controls had Montreal Cognitive Assessment (MoCA) ≥ 26 (study 134 
1) or Addenbrookes Cognitive Examination 3 (ACE-III) ≥ 88 (study 2). 7 participants originally 135 
recruited as healthy controls in study 1 were found to have MoCA scores of < 26, so were 136 
reclassified as MCI (given the high sensitivity and specificity of the MoCA for detecting MCI at this 137 
threshold; 90% and 100%, respectively (Nasreddine et al., 2005)).  138 
Subjects for both studies were recruited from local GP surgeries and memory clinics in the Bristol 139 
area (having received MCI diagnoses or reported memory problems), Join Dementia Research, Avon 140 
and Wiltshire Mental Health Partnership’s Everyone Included system, an in-house database of 141 
volunteers, replies to poster adverts or through word of mouth. All patients provided informed 142 
written consent prior to testing as according to the Declaration of Helsinki. Ethical approval was 143 
given by Frenchay NHS Research Ethics Committee. 144 
The current analyses included all participants who had both volumetry and T2 relaxometry data for 145 
hippocampal subfields, study 1 n=91 (50 HC, 30 MCI), study 2 n=66 (49 HC, 19 MCI). See tables 1 146 
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and 2 for demographic details. A total of 20 MCI participants were followed-up after one-year (10 147 
from each study), representing a relatively high dropout rate from the MCI cohort.  148 
Cognitive testing 149 
Cognitive function was tested at baseline and follow-up using the MoCA in study 1 and the ACE-III 150 
in study 2.  151 
Participants in both studies carried out the paired associates learning (PAL) task of the CANTAB 152 
toolbox which has shown high sensitivity to cognitive impairment and daily functioning in dementia 153 
(Égerházi et al., 2007). 154 
Imaging parameters 155 
Scans for both studies were acquired on a Siemens Magnetom Skyra 3T system equipped with a 156 
parallel transmit body coil and a 32-channel head receiver array coil. The two studies used similar, 157 
but slightly different scanning protocols. 158 
Study 1 159 
This protocol has been previously described by Knight et al. (2019). The imaging protocol included a 160 
3D T1-weighted whole-brain magnetization prepared rapid acquisition gradient-echo (MPRAGE) 161 
and 2D multi-contrast multi-spin-echo (CPMG). 162 
MPRAGE: Coronal, whole-brain, repetition time (TR) 2200 ms, Echo Time (TE) 2.42 ms, Inversion 163 
time (TI) 900 ms, flip angle 9°, acquired resolution 0.68 x 0.68 x 1.60 mm, acquired matrix size 152 164 
x 320 x 144, reconstructed resolution 0.34 x 0.34 x 1.60 mm (after two-fold interpolation in-plane by 165 
zero-filling in k-space), reconstructed matrix size 540 x 640 x 144, GRAPPA factor 2. Acquisition 166 
time: 5:25 min.  167 
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CPMG: Coronal, TR 4500 ms, TE 12 ms, number of echoes 10, echo spacing 12 ms, acquired 168 
resolution 0.68 x 0.68 x 1.7 mm inclusive of 15% slice gap, acquired matrix size 152 x 320, 34 169 
slices, interleaved slice order, reconstructed resolution 0.34 x 0.34 x 1.7 mm (after two-fold 170 
interpolation in-plane by zero-filling in k-space, and inclusive of 15% slice gap), reconstructed 171 
matrix size 540 x 640, 34 slices, GRAPPA factor 2. Acquisition time: 11:07 min.  172 
Study 2 173 
This protocol has been previously described by Wearn et al. (2020a). 174 
The imaging protocol included a 3D T1-weighted whole-brain MPRAGE and 2D multi-contrast 175 
turbo spin-echo (TSE). 176 
MPRAGE: Sagittal, whole-brain, TR 2200 ms, TE 2.28 ms, TI 900 ms, flip angle 9°, FOV 220 x 220 177 
x 179 mm, acquired resolution 0.86 x 0.86 x 0.86 mm, acquired matrix size 256 x 256 x 208. 178 
Acquisition time: 5:07 min. 179 
Multi-contrast TSE: Coronal, TR 7500ms, number of echoes: 3, TE 9.1, 72 & 136 ms, acquired 180 
resolution 0.69 x 0.69 x 1.5 mm, reconstructed resolution 0.34 x 0.34 x 1.5 mm (after 2-fold 181 
interpolation in-plane by zero-filling in k-space, and inclusive of 15% slice gap), GRAPPA factor 2, 182 
FOV 220 x 220 x 34, acquired matrix size 270 x 320 x 58. Acquisition time: 5:09 min. 183 
CPMG and TSE scans were not ‘whole-brain’, their coverage only extending approx. 1cm beyond 184 
anterior and posterior ends of the hippocampus. These scans were tilted such that the hippocampal 185 
body lay perpendicular to the slice acquisition plane.  186 
The two distinct methods of measuring quantitative T2 (CPMG vs TSE) will give inherently 187 
different values for T2 midpoint and heterogeneity between studies (See supplementary information). 188 
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Relationships to variables such as age and cognitive score should be similar, given they are sensitive 189 
to the same tissue properties. 190 
Imaging analyses 191 
All analyses were performed at CRICBristol in a Linux cluster environment. All analyses were 192 
carried out in single-subject native space. 193 
CPMG and TSE scans were brain-extracted using FSL’s bet2 on the first echo in the series (Smith, 194 
2002). All extracted images were visually inspected for quality and rerun with different fractional 195 
intensity thresholds or gradient parameters where necessary. Fractional intensity threshold was 196 
typically set between 0.2-0.3. MPRAGE images were brain-extracted using vbm8bet (in-house 197 
script) and bias-field-corrected using FSL FAST (Zhang et al., 2001). T2 maps were created in 198 
MATLAB from multi-echo sequences by fitting logarithmic-space mono-exponential decay 199 
functions to each voxel series (overall summary of T2 calculation is shown in Knight et al. (2019)). 200 
The first echo of CPMG was always excluded. A sum-of-echoes image was created in order to have 201 
one structural image representing the entire multi-echo sequence. This image was used for 202 
segmentation. 203 
Hippocampus was automatically masked using the Automatic Segmentation of Hippocampal 204 
Subfields (ASHS) software package (Yushkevich et al., 2015) (version: rev103, dated 12/06/2014; 205 
UPENN memory centre atlas dated 16/04/2014).  This atlas contains a demographically similar 206 
template set to the present studies (healthy older adults and people with MCI). ASHS has 207 
demonstrated high accuracy whilst minimising subjective rater bias, without the need for group 208 
blinding (Example output shown in Figure 1). CA1, CA2 and CA3 were pooled to create a total 209 
“CA” mask, given the small size of CA2 and CA3. The outermost 1 voxel layer of each subfield was 210 
eroded before T2 histograms were calculated, in order to minimise the effects of partial voluming 211 
and extraneous brain areas confounding T2 histogram analyses. Pilot data (Knight et al., 2019) show 212 
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that using this method, extreme T2 values are not located around the outside border of the subfields, 213 
which would indicate strong partial voluming effects. Eroded subfield masks were overlaid onto T2 214 
maps, giving a value of T2 for each voxel within each subfield.  215 
 216 
Figure 1 | ASHS MTL mask example with subfields labelled.  217 
Each row shows unmasked (left) and masked (right) coronal slices of a healthy control MTL on summed-over-echoes T2-weighted 218 
scan. Top row shows hippocampal head, bottom row shows hippocampal body. DG = Dentate Gyrus, CA = Cornu Ammonis 1-3, 219 
SUB=Subiculum, EC = Entorhinal Cortex, BA = Brodmann Area. Misc and BA36 were excluded from all analyses. [COLOUR 220 
FIGURE] 221 
Modelling T2 heterogeneity 222 
T2 distribution histograms were modelled as loglogistic distributions within each subfield, as this 223 
was found to be the best fitting overall model in the whole hippocampus (Wearn et al., 2020a). Log-224 
logistic distribution is defined as:  225 






[1 + exp (z)]2
 , 𝑤ℎ𝑒𝑟𝑒 𝑧 =  





where μ and σ denote the log-median value (midpoint) and distribution shape (heterogeneity), 227 
respectively. These descriptors of log-logistic distribution are analogous to median and median 228 
absolute deviation on a normal distribution. The models are described in more detail by Wearn et al. 229 
(2020a). 230 
Statistical analysis 231 
Volumes, T2 parameters and g eneral cognitive scores (MoCA / ACE-III) were pooled 232 
between studies after being converted into Z-scores for each study separately, with the left DG of 233 
healthy controls of each study as a reference point. In doing this, group, subfield, and hemisphere 234 
differences were maintained within each population.  235 
We used a mixed model analysis, using the ‘fitlme’ MATLAB function, to assess differences in T2 236 
parameters between groups (HC, MCI), subfields (DG, CA, SUB, EC, BA35), hemispheres (left, 237 
right) and the effect of age. Full factorial models were created (assessing intercept and all possible 238 
interactions of aforementioned variables) with random effects of subject, subject*subfield 239 
interaction, and subject*hemisphere interaction. Each random effect significantly improved the 240 
model fit (as measured by AIC), without overparameterizing the model (confirmed by checking the 241 
hessian matrix and AIC). Age of the entire cohort was converted to a Z-score before being entered 242 
into the model. Models were created using Restricted Maximum Likelihood Estimation. Degrees of 243 
freedom were calculated using Satterthwaite approximation. A separate model was created for each 244 
of T2 midpoint (T2μ) and T2 heterogeneity (T2σ).  Because of the inclusion of age in the models, all 245 
results are appropriately corrected for the effect of age.  246 
Between-group post hoc comparisons were assessed using independent-samples t-tests. Cohen’s d 247 
values for each comparison are reported as a measure of effect size. Post hoc effects of age in each 248 
subfield are assessed using linear regression. 249 
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Ability of volume and T2 in MTL subfields to predict cognitive decline (as measured by MoCA / 250 
ACE-III) was assessed using stepwise linear regression with forward selection. Forward stepwise 251 
regression works by first adding the variable (subfield) which best improves model fit (if any), then 252 
continuing to add variables which further significantly improve model fit. The criteria for adding 253 
more variables was a significant F statistic at the p<0.05 level. We entered follow-up cognition as the 254 
dependent variable and baseline cognition and age as fixed covariates: 255 
Follow-up Cognition256 
= 𝛽𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 +  𝛽𝑎𝑔𝑒(Age) +  𝛽𝐵𝐿𝐶𝑜𝑔(BaselineCognition) + [𝛽𝐶𝐴(CA) + 𝛽𝐷𝐺(DG)257 
+ 𝛽𝑆𝑈𝐵(SUB) + 𝛽𝐸𝐶(𝐸𝐶) + 𝛽𝐵𝐴35(𝐵𝐴35) + 𝛽𝐻𝑖𝑝𝑝(𝐻𝑖𝑝𝑝)] + error  258 
Parameters in square brackets represent those entered in a stepwise fashion. ‘Hipp’ represents total 259 
hippocampus. This analysis was performed for the MCI cohort only given the greater variability 260 
within this group. Z-scores for this analysis were calculated relative to each study’s MCI population 261 
only. This method of predicting follow-up cognition whilst correcting for baseline cognition 262 
represents a more precise and less biased way of assessing cognitive change over time, compared to 263 
using change scores, as described by Vickers and Altman (2001). 264 
We assessed the relationship between age, subfield T2 heterogeneity, subfield volume (ICV-265 
corrected) and memory using path analysis. Memory was assessed using two measures of 266 
performance on the PAL task – total accuracy and mean reaction time across all trials. We took a 267 
semi-supervised approach when defining the model paths. The direction of the arrows was 268 
predetermined by theory; T2 heterogeneity is caused by microstructural changes that precede 269 
significant atrophy. In this regard, volumes were not allowed to predict T2. Memory scores were not 270 
allowed to predict structural variables, and, for obvious reasons, no variable was allowed to predict 271 
age. All direct effects in this direction were modelled and compared. Initially the model was run with 272 
both PAL scores in a single model, feeding into a single latent variable representing overall PAL 273 
score. However, we observed poor factor loadings of each score onto the latent variable (<.60), so 274 
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ran two separate models instead each with a single PAL outcome measure. Error terms were added to 275 
all variables except age and covariances and modification indices were calculated between all terms. 276 
All error term pairs within a structural measure (T2σ or volume) that had significant modification 277 
indices were allowed to covary, substantially improving overall model fit. In other words, subfields 278 
were allowed to covary within (but never between) each MRI modality. We observed poor model fit 279 
when data was entered as Z-scores normalised to left DG of HCs of each study as described above. 280 
We therefore normalised each structural measure to only the respective HC population, such that the 281 
mean ± standard deviation for each structural measure within any given subfield was 0 ± 1. In other 282 
words, differences between subfields were not considered by the model. This improved model fit to 283 
acceptable levels and should be considered in interpretation of the data.  284 
Finally, we ran partial correlations to explore the relationship between absolute volume (uncorrected 285 
for intracranial volume) and T2 heterogeneity, correcting for age in healthy controls. The results of 286 
this analysis are presented in supplementary table 8. 287 
All reported p-values are two-tailed. Where possible we have used comprehensive models, to 288 
minimise the need for multiple comparison corrections. False discovery rate (FDR) correction 289 
(Benjamini and Hochberg, 1995) was applied to individual paths and indirect paths in the path 290 
analysis, in line with guidance from Cribbie (2007). Data handling and storage was carried out using 291 
MathWorks MATLAB 2015a (with statistics and machine learning toolbox) and Microsoft Excel 292 
2016. Mixed models were created and assessed in MathWorks MATLAB 2018a. Other statistical 293 
analyses were performed in IBM SPSS Statistics 24. Graphs were produced using GraphPad Prism 294 




Participant demographics 297 
Demographic information for the cohort is displayed in Table 1. Our healthy control and MCI groups 298 
are closely matched for age and years of education. Details of cohorts in study 1 and study 2 are 299 
separately displayed in supplementary tables 1 and 2. 300 
Table 1 | Participants demographics 301 
Cognitive score was calculated using MoCA (study 1) and ACE-III (study 2). Because of the different measures used between studies, 302 
each score was first normalised to each study’s respective HC group, before being pooled here. Asterisks represent unpaired t-tests 303 
between groups (*p<0.05, ***p<.0001). YOE = Years of Education, HC = Healthy Control, MCI = Mild Cognitive Impairment.  304 
 HC MCI Total 
N (male: female) 99 (47:52) 49 (27:22) 148 (74:74) 
Age (years) 69.2 ± 8.55 72.2 ± 9.03 70.2 ± 8.79 
YOE 15.8 ± 3.13 *14.2 ± 2.81 15.3 ± 3.11 
Cognitive score 
(normalised to HC) 
.000 ± 1.00 ***-3.75 ± 2.42 -1.25 ± 2.39 
 305 
 306 
Part 1: T2 changes in MCI 307 
T2 heterogeneity 308 
In addition to the overall effects of group (F(1,144)=17.7, p<.0001) and subfield (F(4,576)=262, 309 
p<.0001; explored further in supplementary information) and in line with hypothesis 1, the mixed 310 
model analysis revealed a significant group*subfield interaction (F(4,576)=5.01, p=.001). This effect 311 
did not vary according to hemisphere so a two-way ANOVA on pooled hemispheres was conducted 312 
with predicted values from the mixed model analysis, with pairwise group comparisons for each 313 
subfield (Figure 2). This test revealed a significantly greater T2 heterogeneity in the MCI group in all 314 
subfields but with varying effect sizes (DG: t=3.26, pcorr =.008, Cohen’s d=0.59; CA: t=3.79, pcorr 315 
=.001, Cohen’s d=0.68; SUB: t=5.50, pcorr <.0001, Cohen’s d=0.99; EC: t= 6.63, pcorr <.0001, 316 
Cohen’s d=1.22; BA35: t=5.26, pcorr <.0001, Cohen’s d=0.96, all adjusted using Bonferroni 317 





Figure 2 | Subfield comparisons for T2 heterogeneity and absolute T2.  321 
Violin plots showing group & subfield differences (pooled across hemispheres & corrected for age) for absolute T2 and heterogeneity 322 
marginal means. HC = healthy older control; MCI = mild cognitive impairment. Stars represent p-values from post hoc two-way 323 
ANOVA tests to compare subfield groupwise differences. **p<.01; ***p<.001; ****p<.0001. [COLOUR FIGURE] 324 
We also found a significant main effect of age (F(1,144)=37.6, p<.0001) and an interaction between 325 
subfield and age (F(4,576)=10.4, p<.0001). Older people had significantly increased T2 326 
heterogeneity in all subfields. The association increased in strength in a stepwise fashion through DG 327 
(R2=.106, F(1,146)=17.3, pcorr=.0003), CA (R
2=.147, F(1,146)=27.5, pcorr<.0001), SUB (R
2=.159, 328 
F(1,146)=27.5, pcorr<.0001), EC (R
2=.185, F(1,146)=33.2, pcorr<.0001) and BA35 (R
2=.227, 329 
F(1,146)=42.8, pcorr<.0001). 330 
Finally, we observed no interactions between group and age (F(1,144)=1.74, p=.190) or group and 331 
hemisphere (F(1,144)=0.31, p=.579) nor were there any three- or four-way interactions for T2 332 
heterogeneity. 333 
Absolute T2 334 
For comparison, we also explored subfield-specific changes in absolute T2. In contrast to T2 335 
heterogeneity we observed no overall difference between HC and MCI groups on absolute T2 336 
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(F(1,144)=1.19, p=.278), but did see a substantial overall difference in absolute T2 between subfields 337 
(F(4,576)=974, p<.0001; explored further in supplementary information). We found a 338 
group*subfield interaction (F(4,576)=3.78, p=.005) driven by a subiculum-specific low T2μ in the 339 
MCI group (t=5.50, pcorr<.0001, Cohen’s d=0.95). In no other subfield was there any difference 340 
between groups. 341 
Although we observed no significant main effect of age on absolute T2 (F(1,144)=0.01, p=.907) , the 342 
model did reveal a significant interaction between subfield and age (F(4,576)=2.92, p=.021). 343 
However, in no subfield was there any statistically significant association between age and absolute 344 
T2 (all subfields: p > .250). 345 
We observed no interactions between group and age (F(1,144)=.005, p=.946) or group and 346 
hemisphere (F(1,144)=1.65, p=.201) nor were there any three- or four-way interactions for absolute 347 
T2. 348 
Predicting cognitive change over time 349 
In order to identify whether MTL subfields could predict cognitive decline, we ran three stepwise 350 
linear regressions to predict cognitive score of people with MCI after one year. One model was run 351 
for each MRI modality: volume, T2 heterogeneity, absolute T2, whilst always accounting for 352 
baseline cognitive score and age. Age and baseline cognition alone were unable to significantly 353 
predict follow-up cognitive score (R2=.092, F(2,19)=.859, p=.441; AIC=29.9). In other words, age 354 
alone was unable to predict the degree of cognitive change over the year.  355 
Of all three modalities, only T2 heterogeneity could accuracy predict cognitive change over time. In 356 
this model, greater T2 heterogeneity within EC predicted poorer cognition after the year (R2=.406, 357 
F(3,19)=3.65, p=.035, AIC=23.4; βEC=-.665, p=.010). No additional subfields sufficiently increased 358 
the model fit to qualify for entry into the model.  359 
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EC volume was entered as sole predictor of greater cognitive decline in the volume model (βEC=.595, 360 
p=.030). However the full model was not statistically significant (R2=.329, F(3,19)=2.62, p=.087, 361 
AIC=25.8), indicating a weak association between subfield volume and cognitive change. Similarly, 362 
absolute T2 in DG was selected as a significant predictor of cognitive score after one year, with 363 
higher values predicting greater cognitive decline (βDG=-.494, p=.044), however the overall absolute 364 
T2 model was not statistically significant (R2=.301, F(3,19)=2.30, p=.117, AIC=26.6).  365 
 366 
Figure 3 | Subfield structure predicting cognitive decline in people with MCI 367 
Partial residual (PR) plot of significant model from stepwise linear regression. Graph shows linear regression lines (solid lines) ± 368 
95% confidence intervals (dotted lines). The only significantly predictive model created was that involving T2 heterogeneity within 369 
entorhinal cortex (EC). [COLOUR FIGURE] 370 
 371 
Part 2: Sequential relationships across brain structure and behaviour  372 
We used path analysis to explore predicted relationships between age, T2 heterogeneity, subfield 373 
volume (relative to intracranial volume) and cognition. We took a semi-supervised approach when 374 
defining the model paths. The direction of the arrows was predetermined on the theoretical basis that 375 
T2 heterogeneity is likely caused by microstructural changes that precede significant atrophy. 376 
Memory scores were outcome variables, so were not allowed to predict structural variables, and no 377 
variable was allowed to predict age. All direct effects in this direction were modelled and compared. 378 
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Two separate models were created, one for each of the PAL output measures (See Methods). After 379 
applying covariance structures to error terms between subfields, model fit was good with various fit 380 
parameters falling within an acceptable range (χ2=21.8, df = 20, p=.350; Cmin/DF=1.09; GFI=.964, 381 
AGFI=.861; CFI=.998; RMSEA=.031 ± 90% CI [<.001-.096]; pclose
=.615). Model fit was identical 382 
between the two models. Covariance matrices can be found in supplementary information 383 
(Supplementary Tables 4 & 5).  384 
The final path analysis models (Figure 4) reveal the following relationships, for which statistics are 385 
shown in Table 2 and Supplementary Table 3. Age is a significant positive predictor of T2 386 
heterogeneity in all MTL subfields. In turn, T2 heterogeneity within each subfield is a significant 387 
negative predictor of subfield volume. The only significant direct effects of age on subfield volume 388 
are seen with DG and CA (where greater age predicts smaller volumes), however, significant indirect 389 
effects are seen between age and subfield volume within all subfields (Table 2). T2 heterogeneity 390 
therefore at least partially mediates the relationship between age and volume. 391 
 
Figure 4 | Path analysis showing the relationship between Age, T2 heterogeneity, volume and memory in MTL subfields in 
healthy older controls. 
Bold arrows represent statistically significant relationships (p<.05), with standardized B values indicated in overlaid boxes. Paths 
that do not survive FDR correction for multiple comparisons are marked with †. Two models were run, each assessing one outcome 
measure of the PAL task. Black lines represent paths shared between the models. Unique paths to each model are shown in red 
(PAL reaction time as dependent variable) and blue (PAL Total Accuracy as dependent variable). Curves lines represent error term 
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covariances defined in the model. All subfield volumes were normalised to ICV prior to entering into the model. Full statistics are 
shown in Supplementary Table 3. [COLOUR FIGURE] 
No significant direct effects were observed between T2 heterogeneity and either PAL score (Table 392 
2). However, a direct negative effect of CA volume on PAL mean reaction time was observed, as 393 
well as a direct positive effect of BA35 volume on PAL accuracy. In contrast, we also see that DG 394 
volume has a direct negative relationship with PAL accuracy. The indirect relationship between T2 395 
heterogeneity for each of these respective subfields and each respective PAL score is statistically 396 
significant (Table 2), indicating a role of volume as a mediator between T2 heterogeneity and 397 
cognition. Interestingly, analysis of indirect paths also reveals a marginally significant positive 398 
relationship between DG T2 heterogeneity and PAL reaction time.  399 
Finally, outside of MTL subfield structure and microstructure, we also observe direct effects of age 400 
on PAL scores, with greater age predicting poorer scores on both measures (Table 2).  401 
This all serves to show a clear pathway of the effect of age on cognition, first through its increasing 402 
of T2 heterogeneity in subfields, which in turn reduces the volume of each subfield, which then, in a 403 
subfield-specific manner, reduces cognitive functionality. The full indirect pathway from age, 404 
through T2 heterogeneity, to volume and finally to PAL score is statistically significant for pathways 405 
through DG and BA35 for predicting PAL accuracy, and through CA for predicting PAL reaction 406 
time (Table 2). Outside any MTL subfield paths, there remains a direct effect of age on PAL score, 407 
whereby greater age predicts poorer performance (lower accuracy, longer reaction times), suggesting 408 
that age affects PAL performance through non-hippocampal as well as hippocampal pathways.   409 
We ran the models again on the MCI group data to explore any differences in path structure to the 410 
HC models. We observed no major changes between the models other than the loss of the direct 411 
relationship between age and PAL scores. We also ran a model with the volumes allowed to predict 412 
T2 heterogeneity. this reverse path analysis shows that T2σ does not have the same mediatory effect 413 
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on volume that volume has on T2σ and has poorer model fit parameters. These models will not be 414 
discussed further here as they are not the focus of this study, but the model path diagrams can be 415 
seen in supplementary information (supplementary figures 1 & 2 and supplementary tables 4 & 5). 416 
 417 
Table 2 | Summary statistics of key indirect paths  418 





Age → T2 heterogeneity → Volume     
 
DG -.072 *.002 
CA -.079 *.002 
SUB -.093 *.002 
EC -.103 *.005 
BA35 -.087 *.009 
 
   









 DG .063 *.020 
CA -.044 .175 
SUB -.032 .177 
EC .008 .753 
BA35 -.059 *.013 
 












DG -.050 .130 
CA .140 *.002 
SUB -.040 .173 
EC -.009 .592 
BA35 .021 .220 
 
   










DG .016 *.013 
CA -.016 .135 
SUB -.012 .131 
EC .003 .749 
BA35 -.024 *.011 
Total path (all subfields) -.006 .183 
 













DG -.013 .096 
CA .049 *.002 
SUB .056 .137 
EC -.004 .585 
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BA35 .009 .183 
Total path (all subfields) .019 .174 
 420 
 421 
DISCUSSION  422 
Here we have shown that T2 heterogeneity in the MTL increases with cognitive impairment in a 423 
subfield-dependent manner in line with progression patterns of Alzheimer’s pathology. We also 424 
show that T2 heterogeneity in the entorhinal cortex predicts cognitive decline in people with MCI 425 
where volume or T2 changes in any other subfield cannot. Furthermore, we describe a mechanism by 426 
which cognitive ability deteriorates with age through direct effects on T2 heterogeneity, which lead 427 
to the changes in volume which in turn lead to cognitive decline. These findings are discussed in 428 
detail below.  429 
Subfield-specific differences in T2 heterogeneity in MCI and with age 430 
T2 heterogeneity was greater in MCI across all subfields of the MTL, however the magnitude of this 431 
effect differed between subfields. The smallest increase was seen in DG, and the largest in EC and 432 
BA35. This is in line with literature on the timing of deposition of NFTs  throughout the course of 433 
AD (Braak and Braak, 1991, Braak and Braak, 1995), whereby the transentorhinal region 434 
(comprising BA35 and lateral EC) is affected first, and DG pathology is only detectible later on. DG 435 
is also one of the last MTL regions to exhibit volume loss (Daugherty et al., 2015). This accordance 436 
between the pattern of T2 heterogeneity differences and AD neuropathological progression supports 437 
T2 heterogeneity as a means to detect pathologically relevant change before the onset of dementia.  438 
This is in contrast to absolute T2, which is no different between healthy controls and people with 439 
MCI in any subfield other than subiculum (where it is decreased in MCI). The effect may be 440 
explained by an increase in iron and compact amyloid plaques, which have been seen to be increased 441 
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in SUB and CA1 regions compared to DG and CA3 in a mouse model of AD (Reilly et al., 2003). 442 
Even though we cannot directly show the prevalence of AD pathology in our MCI sample, these 443 
results are in line with this group being at higher risk for displaying AD pathology.  444 
Our findings support our proposal (Knight et al., 2019, Wearn et al., 2020a) that T2 heterogeneity 445 
defines hippocampal integrity at the subfield level better than absolute T2. In further support of this 446 
model, two studies of absolute T2 in hippocampal subfields in vitro (Huesgen et al., 1993, Antharam 447 
et al., 2012) note a lack of any consistent pattern between healthy control and Alzheimer’s slices in 448 
any subfield.  449 
Clinical Utility of T2 heterogeneity in MTL subfields 450 
We show that T2 heterogeneity in EC could predict cognitive decline in our MCI cohort, where 451 
volume or absolute T2 in whole hippocampus or other MTL subfields could not. Measuring T2 452 
heterogeneity in EC may therefore provide the best chance to identify those who have MCI due to 453 
incipient Alzheimer’s disease as opposed to other causes, though further testing is required to 454 
confirm this.  455 
T2 heterogeneity in the EC possessed the greatest power for predicting cognitive decline of the 456 
subfields tested. EC structure has repeatedly been shown to better predict conversion to Alzheimer’s 457 
disease than hippocampal structure (most often measured by volume or thickness, reviewed by Zhou 458 
et al. (2016)). However, it is interesting to note that EC is selected as a better predictor over BA35, 459 
despite BA35 supposedly being an earlier NFT deposition site in AD. One reason could be that the 460 
transentorhinal cortex spans both regions, and that subsequent microstructural changes are more 461 
widespread across EC compared to BA35 in MCI, supported by histological data (Braak and Tredici, 462 
2015). It is important to note that other subfields were unable to improve model fit as a likely result 463 
of shared variance being explained by each subfield. In other words, we cannot conclude that the 464 
predictive power provided by EC was ‘significantly greater’ than that provided by other subfields. 465 
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Rather, other subfields did not provide a significant amount of additional information on top of that 466 
provided by heterogeneity in EC. 467 
The use of T2 heterogeneity is highly translatable to clinical settings. MRI is standard practice in 468 
improving the accuracy of a diagnosis of AD. The MRI scan necessary to calculate quantitative T2 469 
can be completed within a few additional minutes of a standard clinical MRI (a multi-echo T2 470 
sequence of sufficient resolution is all that is required). The same high-resolution scan can be used to 471 
automatically segment subfields of the MTL e.g. using ASHS (Yushkevich et al., 2015). Although 472 
the use of MRI in people with dementia can sometimes be tricky due exacerbated feelings of 473 
claustrophobia and confusion, this MRI protocol would be most useful in prodromal stages of the 474 
disease, before significant MTL volume loss and symptom severity, minimizing these complications. 475 
A cheaper theoretical screening test with high sensitivity for detecting pathology such as has been 476 
shown with tests of accelerated forgetting on word list tasks (Wearn et al., 2020b, Weston et al., 477 
2018) or a blood test (Toombs and Zetterberg, 2020) may identify individuals who should qualify for 478 
an MRI scan sensitive to very early pathological hallmarks.  479 
Our method of measuring heterogeneity of an MRI signal is arguably a form of texture analysis, a 480 
technique for detecting microstructural changes on MRI whose clinical applications are increasingly 481 
a topic of interest (for a review see Cai et al. (2020)). Zhao et al. (2020) highlight the use of 482 
‘radiomic biomarkers’ (a method of texture analysis) as a robust method of predicting longitudinal 483 
change, and genetic risk for Alzheimer’s disease. Similarly, Sørensen et al. (2017) find that various 484 
measures of hippocampal structure including volume and texture can accurately discriminate healthy 485 
older people from those with MCI and Alzheimer’s disease. To our knowledge, no study has 486 
attempted texture analysis using quantitative T2, or in MTL subfields, making this study the first of 487 
its kind. This appears to be an emerging field with increasing potential for scientific interest and 488 
clinical application. 489 
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Although we have focussed on T2 changes due to Alzheimer’s pathology, T2 heterogeneity is a 490 
novel measure which could be applied to any neurological disease characterised by microstructural 491 
changes, including other dementias, acute stroke (as demonstrated by Norton et al. (2017)), epilepsy 492 
or schizophrenia. Future research could utilise T2 heterogeneity to easily probe microstructural 493 
abnormalities. This study builds on our past analyses of T2 heterogeneity by highlighting how it can 494 
reveal structural changes on an even finer scale, indicating its usefulness in disorders where brain 495 
damage is highly localised.  496 
Subfield-specific contributions to memory  497 
We aimed to better understand the relationship between T2 heterogeneity, volume, age and cognitive 498 
ability in cognitively healthy older people. To summarise, our path analysis revealed the following 499 
pattern of relationships. T2 heterogeneity mediates the negative relationship between age and 500 
volume. Volume in turn mediates the negative relationship between T2 heterogeneity and memory, 501 
in a subfield-specific manner. In line with hypotheses 3 and 4, increased T2 heterogeneity therefore 502 
seems to represent a state of structural damage which may give rise to the volumetric changes which 503 
have the most profound impact on memory and cognition. Interestingly, we do still find a direct 504 
association between age and CA and DG volume, indicating only partial mediation by T2 505 
heterogeneity in these regions. This suggests that there are other age-mediated volumetric changes 506 
which are not accurately reflected by changes in T2 heterogeneity.  507 
Our results reveal potential subfield-specific associations with memory scores unlike previous 508 
similar models that have looked at whole hippocampus only (Rodrigue et al., 2012). Longer reaction 509 
times were associated with a subtle damage to the CA region, whereas poor accuracy was associated 510 
with low BA35 integrity but a more intact DG. This latter result was surprising but may suggest that 511 
an impaired BA35 relative to DG is indicative of a network prone to specific deficits in total 512 
accuracy. This pattern reflects changes seen in early AD, as the transentorhinal cortex is the first 513 
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region to display NFT deposition, and DG is the last of all regions tested (Braak and Braak, 1995, 514 
Braak and Braak, 1991, Xie et al., 2018). In other words, patterns of very subtle neurodegeneration 515 
akin to those found in the earliest stages of AD may give rise to specific deficits in total accuracy 516 
scores on the CANTAB PAL. It should be noted that this explanation is speculative and is subject to 517 
confirmation in other cohorts. Indeed, the relationship between DG volume and PAL accuracy does 518 
not appear to survive FDR correction for multiple comparisons and may therefore simply be an 519 
artifact of the modelling procedure. Nonetheless it indicates a point of interest for future studies to 520 
examine hippocampal subfield specificity to behavioural measures, and to further explore to what 521 
degree individual subfield structural changes may indicate early signs of pathology. 522 
Limitations 523 
The main limitation is the lack of biomarker status availability for people with MCI in this study 524 
(assessed either from Positron Emission Tomography or CSF analysis). Therefore, we cannot be 525 
certain as to the exact proportion of those who have incipient dementia. We suspect that T2 526 
heterogeneity in entorhinal cortex would identify those who do have incipient Alzheimer’s disease, 527 
as EC is one of the earliest sites of pathological change. This is supported by the ability of EC T2 528 
heterogeneity in predicting cognitive decline. However, co-pathologies are almost certainly present 529 
in the overall cohort which may include other dementias or undiagnosed microbleeds. 530 
Additionally, both studies utilised different scanning sequences for assessing quantitative T2, giving 531 
inherently different absolute T2 values. For this reason, we were careful to normalise results from 532 
each cohort before combining them. Although a potential confounding factor, we have noted in our 533 
previous study that effects of T2 heterogeneity do not appear to be specific to a sequence (Wearn et 534 
al., 2020a). Rather, we provide evidence that the different sequences are sensitive to the same 535 
physiological changes. This supports the translatability of this measure to clinical settings, where 536 
available sequences for measuring quantitative T2 may vary between sites.  537 
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We also note a potential selection bias in our 1-year follow-up analysis, as we experienced a 538 
relatively high dropout rate of our MCI cohort. Although reasons for not returning were never 539 
formally quantified, this was occasionally due to the participant feeling unable to attend the second 540 
session due to significant cognitive and/or functional decline. Those who declined the most may 541 
therefore be simply missed out of the current analyses. We expect the result of this bias to minimise 542 
the ability of our MRI variables to predict decline, so it is testament to the clinical potential of T2 543 
heterogeneity that it can still predict cognitive decline in this cohort. 544 
Finally, we acknowledge that our masking procedure of hippocampal subfields (automated using 545 
ASHS) has only been verified for measuring shape and volume, not T2 heterogeneity. Measures 546 
could feasibly be biased due to the inclusion of extraneous brain regions or subject to error from 547 
surrounding regions through partial voluming. We have minimised the risk of these factors by 548 
eroding our subfield masks by their outermost voxels. Furthermore, we find no evidence of a 549 
relationship between absolute subfield volume and T2 heterogeneity, indicating that the two 550 
measures are distinct, and not confounded by one another (supplementary information section 4).   551 
Conclusions 552 
The analyses presented in this paper comprise the first detailed exploration of quantitative T2 across 553 
subfields of the medial temporal lobe in older people with and without cognitive impairment. We 554 
support previous evidence that absolute T2 is not a sensitive marker of early pathology, rather, 555 
heterogeneity of T2 is much more sensitive to early pathological change. We demonstrate that T2 556 
heterogeneity differs between subfields in a manner which reflects the order of NFT deposition in 557 
prodromal AD. We provide evidence that although T2 heterogeneity increases with age in all 558 
subfields, the degree to which this occurs is subfield-dependent and is strongest in MTL cortical 559 
regions (EC and BA35). In contrast, we do not see systematic evidence of a relationship between age 560 
and absolute T2. Using path analysis, we describe a pathway through which cognition is significantly 561 
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affected by age through direct effects on T2 heterogeneity in cognitively healthy older people, which 562 
in turn has direct effects on volume which lead to changes in cognition, supporting the idea that T2 563 
changes precede and lead to volumetric changes. Finally, we show that the single best predictor of 564 
cognitive decline in people with MCI is greater T2 heterogeneity within entorhinal cortex, 565 
outperforming both T2 midpoint and, critically, volume of any subfield.  566 
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